Genetic Technologies, MycroLab to collaborate on genetic test for bird flu

By Lisa Kerner

Charlotte, N.C., Aug. 30 - Genetic Technologies Ltd. (GTG) executed a binding term sheet with the Australian-based MycroLab Pty. Ltd. giving GTG the right to market a new genetic test for avian influenza (bird flu) exclusively in Australia, New Zealand, Canada, the United States and Mexico.

The agreement gives MycroLab access to GTG's biomedical scientists and laboratory facilities, while GTG has a first right of refusal to other applications delivered using the MycroLab technology platform.

MycroLab's patented, low-cost miniaturized platform eliminates the need for samples to be sent to a laboratory, according to a news release.

A genetic test for bird flu developed by The Victoria Department of Primary Industry will be miniaturized using MycroLab's platform.

The department's test identified all 16 strains of the bird flu virus and can be adapted to detect any new strains that may develop.

GTG is a Fitzroy, Australia, life sciences company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.